CEST MRI in hematoma could be challenging depending on the involvement of iron. This study examined the feasibility of CEST in monitoring ICH and its progression over two weeks. The AREX data supported that the iron-overloading pathology might not significantly attenuate CEST contrast as demonstrated both in vitro and in vivo at 3T. We observed the most significant decrease in rNOE (37%) and APT (47%) contrast in lesions were on day7 and day3, respectively, when compared to contralateral side. This could indicate neuropathologies related to lipid and amide, which could be valuable for ICH diagnosis and treatment planning at 3T.
This abstract and the presentation materials are available to members only; a login is required.